LBX PHARMACY CHAIN |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.95 CNY | -1.20% |
|
-7.84% | -17.58% |
| May. 15 | Nanhua Futures CFO Steps Down | MT |
| Apr. 29 | LBX Pharmacy Chain Joint Stock Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 26.3B 3.62B | Sales 2025 * | 31.27B 4.3B | Capitalization | 14.41B 1.98B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.12B 155M | Net income 2025 * | 1.38B 189M | EV / Sales 2024 * | 0.59 x |
| Net Debt 2024 * | 1.22B 168M | Net Debt 2025 * | 1.06B 146M | EV / Sales 2025 * | 0.49 x |
| P/E ratio 2024 * |
12.8
x | P/E ratio 2025 * |
10.4
x | Employees | - |
| Yield 2024 * |
3.14% | Yield 2025 * |
3.8% | Free-Float | 46.59% |
More Fundamentals
* Assessed data
More news
More recommendations
| 1 day | -1.20% | ||
| 1 week | -7.84% | ||
| Current month | +3.21% | ||
| 1 month | -26.68% | ||
| 3 months | -20.09% | ||
| 6 months | -21.04% | ||
| Current year | -17.58% |
1 week
18.14
19.92
1 month
18.1426.26
Current year
18.1428.38
1 year
17.5528.38
3 years
16.5335.86
5 years
16.5355.09
10 years
8.3255.09
| Managers | Title | Age | Since |
|---|---|---|---|
Li Wang
DFI | Director of Finance/CFO | 42 | - |
Xia Er Liu
IRC | Investor Relations Contact | - | - |
Shi Ni Feng
SEC | Corporate Secretary | 39 | 19-08-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ming Chuan Ren
BRD | Director/Board Member | 64 | Feb. 21 |
Zi Qi Xie
BRD | Director/Board Member | 47 | 22-03-01 |
Zi Long Xie
FOU | Founder | 57 | 05-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 18.95 | -1.20% | 12,198,430 |
| 24-07-01 | 19.18 | +4.47% | 16,177,540 |
| 24-06-28 | 18.36 | -4.38% | 16,898,640 |
| 24-06-27 | 19.2 | -6.02% | 10,314,190 |
| 24-06-26 | 20.43 | -0.64% | 6,775,396 |
End-of-day quote Shanghai S.E., July 01, 2024
More quotes
LBX Pharmacy Chain JSC is a China-based company principally engaged in the sale of pharmaceuticals, other health and beauty related products. The Company operates its businesses through three segments. Retail segment is mainly engaged in the business of retailing goods. Wholesale segment is mainly involved in the wholesale business of merchandise. Other Business segment is mainly involved in the pharmaceutical manufacturing and other businesses. The Companyâs main products comprise proprietary Chinese and western medicines, Chinese herbal medicines, health maintenance Chinese medicines, health equipment, health foods, general foods, personal care products and household appliances. The Company mainly conducts its businesses in the domestic market.
Sector
Drug Retailers
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
18.95
CNY
Average target price
33.11
CNY
Spread / Average Target
+74.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.58% | 1.98B | |
| -10.22% | 2.93B | |
| -28.76% | 2.81B | |
| +2.93% | 2.49B | |
| -7.16% | 1.77B | |
| +16.97% | 1.42B | |
| -31.19% | 830M | |
| -50.32% | 562M | |
| -0.53% | 423M | |
| +9.95% | 403M |
- Stock Market
- Equities
- 603883 Stock
